Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Replimune Group, Inc. (REPL : NSDQ)

• Company Description    Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of cancer diseases. The company's product pipeline consists of RP1, RP2 & RP3 which are in clinical stage. Replimune Group, Inc. is based in MA, United States. Number of Employees: 152

• Price / Volume Information    Yesterday's Closing Price: $14.53 Daily Weekly Monthly 20 Day Moving Average: 417,693 shares Shares Outstanding: 47.21 (millions) Market Capitalization: $685.96 (millions) Beta: 2.29 52 Week High: $40.22 52 Week Low: $13.05 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -17.21% -9.28% 12 Week -9.75% -2.08% Year To Date -46.38% -36.24%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 500 Unicorn Park - WOBURN,MA 01801 USA ph: 781-222-9600 fax: - ir@replimune.com http://www.replimune.com

• General Corporate Information    Officers Philip Astley-Sparke - Chief Executive Officer and Director Robert Coffin - President and Chief Research & Development Officer Jean Franchi - Chief Financial Officer and Treasurer Kapil Dhingra - Director Hyam Levitsky - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 76029N106 SIC: 2836 Fiscal Year Fiscal Year End: March Last Reported Quarter: 12/01/21 Next Expected EPS Date: 05/19/22 Share - Related Items Shares Outstanding: 47.21 Most Recent Split Date: (:1) Beta: 2.29 Market Capitalization: $685.96 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.60 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.70 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/19/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.56 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -29.55% vs. Previous Quarter: -1.79% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - - 12/31/21 - -23.03 09/30/21 - -20.49 ROA 03/31/22 - - 12/31/21 - -20.99 09/30/21 - -18.77 Current Ratio 03/31/22 - - 12/31/21 - 23.39 09/30/21 - 26.71 Quick Ratio 03/31/22 - - 12/31/21 - 23.39 09/30/21 - 26.71 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - - 12/31/21 - 9.33 09/30/21 - 9.78 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - 0.06 09/30/21 - 0.05 Debt-to-Capital 03/31/22 - - 12/31/21 - 5.30 09/30/21 - 5.10

Powered by Zacks Investment Research ©